MOLAB has been awarded one of the Proof of Concept projects in the recent call of the Spanish National Research Agency. 

In silico clinical trials (ISCTs) are computer simulations that model drugs, devices, or interventions on virtual populations, acting as a digital complement or precursor to real clinical trials to accelerate development, cut costs, and improve safety by testing hypotheses, designing trials, and predicting outcomes before human testing. 

MOLAB's new project TRANSFERMATH (Transferring mathematical models to drive innovation in virtual clinical trials for the biomedical industry) aims to advance early-phase clinical trial design through mechanistic model-based virtual clinical trials (VCTs). The goal is to deliver a proof-of-concept for integrating predictive mathematical models into academic and industrial drug development, enabling data-efficient, ethical, and cost-effective trial optimization. MOLAB researcher will work on two clinician-led trials in rare diseases: CELYVIR-based virotherapy for paediatric brain tumours (Hospital Niño Jesús, Madrid) and denosumab for fibrous dysplasia (NIH, Bethesda). They will also target industrial validation through retrospective simulation of Phase II trials with CROs and pharmaceutical partners, supporting dose optimization and improved trial design within a Model-Informed Drug Development framework.

For more information check out the project's webpage

https://molab.es/transferring-mathematical-models-to-drive-innovation-in-virtual-clinical-trials-for-the-biomedical-industry-transfermath/